We are live on ! Find out more
ATNM icon

Actinium Pharmaceuticals

59 hedge funds and large institutions have $29.3M invested in Actinium Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more call options, than puts

Call options by funds: $535K | Put options by funds: $359K

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 58 → 59 (+1)

0.34% less ownership

Funds ownership: 21.34% → 21.01% (-0.34%)

4% less capital inflows, than outflows

Capital inflows: $1.45M | Capital outflows: $1.51M

6% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 18

Holders
59
Holders Change
+1
Holders Change %
+1.72%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
17
Reduced
18
Closed
6
Calls
$535​K
Puts
$359​K
Net Calls
+$176​K
Net Calls Change
-⁠$235​K

ATNM Hedge Fund Activity: Q4 2023 in Review

59 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q4 2023, worth a combined $29.3M — down 14% from $34.1M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ATNM positions and 6 closed out — a net gain of 1 holder — while 17 added to existing stakes and 18 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $264K. The largest seller was BlackRock, cutting an estimated $376K.

  • 59 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q4 2023, up from 58 in Q3 2023.
  • Funds reported $29.3M of Actinium Pharmaceuticals stock for Q4 2023, down 14% quarter-over-quarter.
  • 7 funds opened new Actinium Pharmaceuticals positions in Q4 2023 and 6 closed out, a net change of +1 holder.
  • The largest Actinium Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $264K added.
  • The largest Actinium Pharmaceuticals seller in Q4 2023 was BlackRock, an estimated $376K sold.

Based on aggregated 13F filings for Q4 2023.